

September 1, 2010

Contact: Michael Beeuwsaert
President & CEO
Numira Biosciences Inc.
Tel: (801) 320-0682
MBeeuwsaert@numirabio.com

**NUMIRA'S BONE IMAGING APPLICATION HIGHLIGHTED BY
SCHERING-PLOUGH BIOPHARMA IN *THE JOURNAL OF ARTHRITIS RESEARCH AND THERAPY***

SALT LAKE CITY, Utah, September 1 , 2010 –Numira Biosciences, a specialty contract research organization and leader in high resolution, 3D imaging services and visualization software for the life science market, is proud to announce that it's Virtual Histology™ technology was recently highlighted in the *Arthritis Research and Therapy* journal. The publication discusses the use of Numira's quantitative imaging technology as a tool to access cortical and trabecular bone mineral densities in both wild type and knock-out mice.

With the combination of MicroCT, proprietary contrast agents and cutting edge software tools, Numira has developed an innovative, nondestructive way to image small animal models. Using this technology, our clients are able to visualize and quantify structural tissue changes in both bone and soft tissue.

The paper, titled "Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors," by Iannis Adamopoulos et al. is now available. Using Numira's bone imaging services, the researchers were able to confirm previous findings in which no abnormalities

existed in either the skeletal structure or bone morphometric analysis in their IL-17A-/- deficient mice.

About Numira Biosciences

Numira is a specialty contract research organization (CRO) that provides powerful imaging solutions for researchers attempting to answer questions related to the onset and progression of disease, drug efficacy, and drug safety in animal models. Through the combination of proprietary stains, high performance visualization software, and MicroCT scanners, we offer a dramatic change in how data is captured, visualized, and analyzed.

For more information on Numira Biosciences, please visit www.numirabio.com

###